The dogs of Australia have spoken.

Photography: ammit, 123RF

This article is sponsored content brought to you by Cenversa.

Antinol® has become a keystone in osteoarthritis management protocols for hundreds of veterinary practices. As a nutraceutical, Antinol® is amongst the most researched and published non-drug compound in veterinary medicine today. Antinol® revolutionised the marketplace when we first launched it in 2018. Pet owners were so impressed with Antinol® that stories of their pets and how Antinol® had changed their lives forever were popping up all over social media. You can read more about some of these success stories on the Antinol® Facebook page (

And then came along the next generation Antinol® RAPID! Over recent months, more and more veterinarians have switched to the new Antinol® RAPID formulation, a formulation that was years in development and has surpassed all expectations.

Antinol® RAPID is the latest advancement of a multimodal approach to canine osteoarthritis management, offering veterinarians an effective, safe and versatile long-term option. Randomised controlled trials have demonstrated the efficacy of Antinol®. Research is ongoing, with force-plate gait analysis alongside NSAIDs and investigations into other indications for skin, cognitive and respiratory support being a priority. Decades of published peer-reviewed research firmly establishes Antinol® and Antinol® RAPID as superior to other natural joint products. 

Antinol® RAPID includes a synergistic, anti-inflammatory blend of two extracts to create EAB-277™. PCSO-524® the active compound from Antinol®, is a marine lipid compound extracted from Green Lipped Mussel Powder via Supercritical Fluid Extraction. Antinol® RAPID contains PCSO-524®in addition to a proprietary high-phospholipid extract from krill via the same process. Whilst effective anti-inflammatory compounds in their own right, laboratory studies have proven that the synergistic blend of EAB-277™ in Antinol® RAPID represents a more potent anti-inflammatory combination, more effective than either product alone. 

Antinol® RAPID has no known contraindications, therefore it can be combined with NSAIDs, Injectables or other pharmaceuticals and supplements for enhanced case management options and long-term patient support. It is also widely used under recommended dosage by dog owners focused on wellness and optimal health. Vets have also shared some successful off-label uses for Antinol®. Due to the unique combination of lipids and absence of any allergenic proteins in the patented active compound EAB-277™, the product is being applied by vets to manage skin and coat health as well as other inflammatory conditions. The use of Antinol® in cats has also been reported by vets, especially as an alternative or adjunctive therapy for NSAIDs in many patients. Antinol® use in cats is considered off-label in Australia, but it is used widely in overseas markets. 

Antinol® RAPID is breaking new ground and delivering even better results for veterinarians and pet owners alike. Antinol® RAPID remains proudly a veterinary exclusive product and unlike the original it has no human equivalent.

If you need more information about Antinol® RAPID, please contact

Cenvet Australia call 1300 CENVET.

Vet Practice magazine and its associated website is published by Engage Media. All material is protected by copyright and may not be reproduced in any form without prior written permission. Explore how our content marketing agency can help grow your business at Engage Content or at


Please enter your comment!
Please enter your name here